menu
    • menu

    Company profile for Sentien Biotechnologies

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Sentien Biotechnologies, Inc. is a privately-owned, clinical-stage company developing novel cell therapies that restore balance to the immune system and transform treatment options for patients with systemic inflammatory diseases. Our innovative blood conditioning approach has been proven to significantly enhance exposure and extend therapeutic activity of Mesenchymal Stromal Cells (MSCs). By immobilizing MSCs in an extracorpo...
    Sentien Biotechnologies, Inc. is a privately-owned, clinical-stage company developing novel cell therapies that restore balance to the immune system and transform treatment options for patients with systemic inflammatory diseases. Our innovative blood conditioning approach has been proven to significantly enhance exposure and extend therapeutic activity of Mesenchymal Stromal Cells (MSCs). By immobilizing MSCs in an extracorporeal device, our flagship SBI-101 product enables sustained, controlled dosage of secreted anti-inflammatory and regenerative properties that are unattainable by direct injection or intravenous infusion.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Sentien BiotechnologiesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Sentien Biotechnologies, Inc. 99 Hayden Avenue Building E, Suite 140 Lexington...
    Telephone
    Telephone
    +1-781-361-9031
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://sentienbiotech.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/sentien-biotechnologies-inc./
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/SentienBiotech

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sentien Partners with BARDA to Evaluate High Dose Cohort of SBI-101
    Sentien Partners with BARDA to Evaluate High Dose Cohort of SBI-101

    03 Sep 2021

    // PRWEB

    https://www.prweb.com/releases/sentien_biotechnologies_partners_with_barda_to_evaluate_high_dose_cohort_in_phase_1_2_trial_of_sbi_101_for_treatment_of_acute_kidney_injury_associated_with_sepsis/prweb18166631.htm

    PRWEB
    03 Sep 2021
    Share Share
    Sentien Announces First Subject Dosed in Phase 1/2 Trial of Ex Vivo MSC
    Sentien Announces First Subject Dosed in Phase 1/2 Trial of Ex Vivo MSC

    23 Nov 2020

    // PRWEB

    https://www.prweb.com/releases/sentien_biotechnologies_announces_first_subject_dosed_in_phase_1_2_trial_of_ex_vivo_msc_therapy_for_the_treatment_of_severe_covid_19/prweb17563398.htm

    PRWEB
    23 Nov 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search